Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
Want to help meet this urgent need? Here are 5 things you need to know.
Why in these uncertain times, community is more important than ever for those with bleeding disorders.
One Alpha 1 patient discusses his daily routine in this Plasma Protein Therapeutics Association video.
Foundation answers who’s most at risk and offered a webinar about mental health during the pandemic.
Communications about COVID-19 go out to those living with hemophilia, von Willebrand disease.
Both work, but experts say one of these methods has the upper hand.
In recognition of International Women’s Day, CSL leaders reflect on the importance of gender diversity for innovation, scienc…
Construction of new CSL headquarters underway in Melbourne.
Doctor’s book tells story of researching his own rare disease.
Americas
Asia Pacific
Middle East
Europe